Crystalline salt forms
Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH 2 .
1. A crystalline form of a mesylate salt of Compound I,
wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.0, 10.4, 11.0, 12.0, 14.9, 19.3, 20.4, and 21.4.
2. The crystalline form of claim 1 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.0, 10.4, 11.0, 12.0, 14.9, 15.7, 18.8, 19.3, 20.4, 20.8, 21.2, 21.4, 21.6, 22.0, 22.5, 22.9, 25.9, and 26.4.
3. A crystalline form of a mesylate salt of Compound I,
wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 3.2, 4.3, 6.0, 12.8, 17.5, 18.9, 20.6, 21.4, and 22.7.
4. The crystalline form of claim 3 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 3.2, 4.3, 6.0, 12.0, 12.4, 12.8, 14.6, 15.8, 15.9, 17.5, 18.4, 18.9, 19.4, 19.8, 20.1, 20.6, 21.4, 22.7, 23.2, 23.8, 24.8, 25.4, and 26.1.
5. A composition, comprising a crystalline form of claim 1 .
6. A process for making a pharmaceutical composition comprising Compound I,
comprising dissolving a crystalline form of claim 1 .
7. A composition, comprising a crystalline form of claim 3 .
8. A process for making a pharmaceutical composition comprising Compound I,
comprising dissolving a crystalline form of claim 3 .